Cargando…

Echocardiographic analysis of acute effects of percutaneous mitral annuloplasty on severity of secondary mitral regurgitation

AIMS: Percutaneous mitral annuloplasty (PMA) represents a new treatment option for secondary mitral regurgitation (SMR) being associated with higher morbidity and mortality. The present study was aimed to evaluate whether or not acute effects on SMR severity can quantitatively be assessed after PMA....

Descripción completa

Detalles Bibliográficos
Autores principales: Stöbe, Stephan, Kreyer, Kristin, Jurisch, Daniel, Pfeiffer, Dietrich, Lavall, Daniel, Farese, Gerardo, Laufs, Ulrich, Hagendorff, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373905/
https://www.ncbi.nlm.nih.gov/pubmed/32358886
http://dx.doi.org/10.1002/ehf2.12719
Descripción
Sumario:AIMS: Percutaneous mitral annuloplasty (PMA) represents a new treatment option for secondary mitral regurgitation (SMR) being associated with higher morbidity and mortality. The present study was aimed to evaluate whether or not acute effects on SMR severity can quantitatively be assessed after PMA. METHODS AND RESULTS: PMA was performed in 30 patients (mean age 76 ± 9; 37% males) with moderate (n = 14) or severe (n = 16) SMR. Vena contracta (VC), left ventricular (LV) velocity‐time‐integral ratio (VTI(MV/LVOT)), effective regurgitant orifice area (EROA) by two‐dimensional proximal isovelocity surface area (PISA), regurgitant volume (RVol(PISA)) and regurgitant fraction (RF(PISA)) by PISA, RVol(volume) and RF(volume) by LV volume analyses, and parameters describing LV morphology, function, and cardiac performance were assessed by transthoracic echocardiography prior to and after PMA. According to RF(PISA)/RF(volume), 14 patients showed mild, 15 moderate, and 1 severe SMR after PMA. Mean RF, RVol, EROA, VC, and VTI(MV/LVOT) were lower directly after PMA (RF(PISA): 49% ± 11 vs. 34% ± 13, P < 0.001; RF(volume): 46% ± 10 vs. 34% ± 13, P < 0.001; RVol(PISA): 33 mL ± 13 vs. 25 mL ± 12, P < 0.001; RVol(volume): 28 mL ± 17 vs. 20 mL ± 14, P < 0.05; EROA(PISA): 0.24 cm(2) ± 0.1 vs. 0.19 cm(2) ± 0.1, P < 0.05; VC: 5.2 ± 0.1 vs. 4.1 ± 0.2, P < 0.001; VTI(MV/LVOT): 1.9 ± 0.4 vs. 1.6 ± 0.5, P < 0.05). Parameters of LV morphology, function, and cardiac performance did not change directly after PMA. CONCLUSIONS: PMA leads to a reduction of MR severity in >80% of SMR patients. Acute effects of PMA can quantitatively be assessed by transthoracic echocardiography.